Navigation Links
Prostate cancer patients treated with robotic-assisted surgery can expect low recurrence of cancer
Date:10/18/2010

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

The findings were reported in this month's issue of the European Urology journal by a team of Henry Ford Hospital researchers led by Mani Menon, M.D., an internationally recognized pioneer in the use of high-precision surgical robots.

In an editorial accompanying the article, the author wrote "it is very clear that the article by Menon et al represents a land mark contribution in the area of PCa (prostate cancer) management."

Dr. Menon, director of Henry Ford's Vattikuti Urology Institute, perfected the technique for minimally invasive laparoscopic treatment of prostate cancer.

Because they were among the first surgeons in the world to use the technique, Dr. Menon and his team had a unique opportunity to test its effectiveness on the long-term survival of a large group of prostate cancer patients.

Radical prostatectomy is a treatment in which the entire diseased prostate gland and some surrounding tissue are surgically removed in hopes of preventing the cancer from spreading to other parts of the body. It has long been considered an effective treatment for localized prostate cancer.

Early studies found that about 35 percent of men suffered a recurrence within 10 years after undergoing traditional radical prostatectomy. But Henry Ford researchers suspected those results might have become outdated as the use of prostate-specific antigen (PSA) screening gained wider acceptance, allowing prostate cancer to be detected in more men at a younger age.

No studies have looked at biochemical recurrence of prostate cancer in patients diagnosed after 2000, when Dr. Menon and his team at Henry Ford began using robot-assisted surgery. Robot-assisted radical prostatectomy has since become the most widely used form of surgical treatment of localized prostate cancer in the country.

But after carefully reviewing the literature since then, Dr. Menon's team found almost no research on medium- to long-term follow-up results.

All 1,384 of the men chosen for study were diagnosed with moderately aggressive prostate cancer and underwent robot-assisted radical prostatectomy between September 2001 and May 2005. Their average age was 60.

The patients were checked for recurrence of their cancer every three months during the first year after surgery, twice during the second year, then annually. A median of five years of follow-up was used for the study.

Dr. Menon or his colleague, James Peabody, M.D., performed all of the robot-assisted surgeries in the study. While both are highly experienced surgeons, they cautioned that the study period included their own learning curve in developing the robot-assisted technique, so results may be difficult to generalize.

Still, they say, the fact that deaths from prostate cancer occurred in only 1 of 1,000 patients per year of follow-up should provide a strong endorsement of the curative role of radical prostatectomy for patients with localized prostate cancer treated in the contemporary era.

And "with five-year actuarial biochemical recurrence-free survival outcomes of 86.6 percent, robot-assisted radical prostatectomy appears to confer effective five-year prostate cancer control."

Henry Ford's robot-assisted urology program uses the da Vinci computer-enhanced, minimally invasive surgery system introduced in 1999 by Intuitive Surgical, Inc. It enables surgeons to manipulate robotic arms for precise procedures through a series of small incisions instead of the large wounds required by traditional open surgery, and provides 3-D monitoring for the entire surgical team. The potential benefits include shorter recovery times, less trauma, and reduced hospitalization costs.

It is also the basis of a nerve-sparing procedure called the Veil of Aphrodite, developed by Dr. Menon to minimize the erectile dysfunction common in men after undergoing traditional radical prostatectomy.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Popular prostate cancer treatment associated with bone decay
2. Surgery offers long-term survival for early stage prostate cancer patients
3. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
4. Surgery found effective for patients with aggressive prostate cancer
5. Cholesterol drug may have role in treating prostate cancer
6. Prostate cancer community calls for better early detection and treatment
7. Urgent need for prostate cancer screening amongst Dutch men
8. Blood test accurately predicts death from prostate cancer up to 25 years in advance
9. Prostate Cancer Screening No Benefit to Older Men With Low PSA Levels
10. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
11. Cost of prostate cancer care varies with initial treatment choice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... autologous fat (adipose) transfer systems announces the issuance of United States Patent Number ... for its adipose filtration technology. The '398 and '324 patents cover methods ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to ... surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one ... world, Allergan is bringing a newly defined structure to the aesthetics market. Dr. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, ... Friday, July 28. , Increased FDA scrutiny and growing demands to track and ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “Nana Nana Boo ... importance of being kind to others. “Nana Nana Boo Boo” is the creation of ... man. , Published by Christian Faith Publishing, Michael Rush’s new book presents the ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... provider of education and training standards for healthcare treatment providers, offers healthcare ... Certification: the iaedp™ Core Curriculum. , Presented as either online or as ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... founder of Echenberg Institute, is announcing a new safe and effective at-home ... and other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, ... ... ... start-up company, VuVatech LLC, fills a void in the women,s wellness market ...
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
Breaking Medicine Technology: